Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents

Behavioural Brain Research

Volumn 285, Issue , 2015, Pages 176-193

  Grayson, Ben ^a   Leger, Marianne ^a   Piercy, Chloe ^a   Adamson, Lisa ^a   Harte, Michael ^a   Neill, Joanna C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer's disease; Autistic spectrum disorder; Object recognition; Parkinson's disease; Schizophrenia; Traumatic brain injury

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANTINEOPLASTIC AGENT; BETA SECRETASE INHIBITOR; BMS 299897; CHOLINESTERASE INHIBITOR; CIPROXIFAN; DONEPEZIL; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; LADOSTIGIL; LEPTIN; LEVODOPA; LIRAGLUTIDE; MELATONIN; MEMANTINE; METHOTREXATE; METRIFONATE; MONOAMINE OXIDASE INHIBITOR; OXALIPLATIN; PALMIDROL; PIROMELATINE; PRAMLINTIDE; ROSIGLITAZONE; SELEGILINE; SILIBININ; TAK 070; TANNIN; THIOTEPA; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; AUTISM; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COGNITIVE DEFECT; COLORECTAL CANCER; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; GENOTYPE ENVIRONMENT INTERACTION; HEADACHE; HEARING IMPAIRMENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMORY; MEMORY DISORDER; MOUSE; NAUSEA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; RECOGNITION MEMORY; RODENT; SCHIZOPHRENIA; TASK PERFORMANCE; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; VISUAL IMPAIRMENT; ANIMAL; COGNITION DISORDERS; PSYCHOLOGIC TEST; RECOGNITION;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MICE; PSYCHOLOGICAL TESTS; RATS; RECOGNITION (PSYCHOLOGY);

EID: 84925359187     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.025     Document Type: Article

References (165)

1. Berlyne D.E. Novelty and curiosity as determinants of exploratory behvaviour. Br J Psychol 1950, 41(1-2):68-80.
2. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988, 31(1):47-59.
3. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology: neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007, 31(5):673-704.
4. Antunes M., Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 2012, 13(2):93-110.
5. Brown M.W., et al. What pharmacological interventions indicate concerning the role of the perirhinal cortex in recognition memory. Neuropsychologia 2012, 50(13):3122-3140.
6. Korosoglou G., et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging 2012, 35(4):804-811.
7. Lyon L., Saksida L.M., Bussey T.J. Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology (Berl) 2012, 220(4):647-672.
8. Meltzer H.Y., et al. Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2013, 16(10):2181-2194.
9. Kamboh M.I. Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 2004, 68(Pt 4):381-404.
10. Alonso Vilatela M.E., Lopez-Lopez M., Yescas-Gomez P. Genetics of Alzheimer's disease. Arch Med Res 2012, 43(8):622-631.
11. Snowden J.S., et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011, 134(Pt 9):2478-2492.
12. Didic M., et al. Impaired visual recognition memory in amnestic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging. J Alzheimers Dis 2010, 22(4):1269-1279.
13. Didic M., et al. Impaired visual recognition memory predicts Alzheimer's disease in amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 2013, 35(5-6):291-299.
14. Mumby D.G., Pinel J.P. Rhinal cortex lesions and object recognition in rats. Behav Neurosci 1994, 108(1):11-18.
15. Ennaceur A., Neave N., Aggleton J.P. Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat. Behav Brain Res 1996, 80(1-2):9-25.
16. Gaffan D. Dissociated effects of perirhinal cortex ablation, fornix transection and amygdalectomy: evidence for multiple memory systems in the primate temporal lobe. Exp Brain Res 1994, 99(3):411-422.
17. Meunier M., et al. Effects on visual recognition of combined and separate ablations of the entorhinal and perirhinal cortex in rhesus monkeys. J Neurosci 1993, 13(12):5418-5432.
18. Delacourte A., et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999, 52(6):1158-1165.
19. Whitwell J.L., et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain: A J Neurol 2007, 130(Pt 7):1777-1786.
20. Zhang R., et al. Novel object recognition as a facile behavior test for evaluating drug effects in AbetaPP/PS1 Alzheimer's disease mouse model. J Alzheimers Dis 2012, 31(4):801-812.
21. Bardgett M.E., et al. Ciproxifan: an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol Learn Mem 2011, 95(1):64-72.
22. Fukumoto H., et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010, 30(33):11157-11166.
23. Gerenu G., et al. Early cognitive stimulation compensates for memory and pathological changes in Tg2576 mice. Biochim Biophys Acta 2013, 1832(6):837-847.
24. Giuliani A., et al. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice. J Neurochem 2013, 124(5):613-620.
25. Martin-Moreno A.M., et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012, 9:8.
26. Mouri A., et al. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007, 21(9):2135-2148.
27. Ohta H., et al. Effects of NK-4 in a transgenic mouse model of Alzheimer's disease. PLoS One 2012, 7(1):e30007.
28. Ribes D., et al. Recognition memory and beta-amyloid plaques in adult Tg2576 mice are not modified after oral exposure to aluminum. Alzheimer Dis Assoc Disord 2012, 26(2):179-185.
29. Sivilia S., et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 2013, 14:44.
30. Taglialatela G., et al. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 2009, 200(1):95-99.
31. Yuede C.M., et al. Effects of voluntary and forced exercise on plaque deposition: hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2009, 35(3):426-432.
32. Chen G., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408(6815):975-979.
33. Dodart J.C., et al. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 1999, 113(5):982-990.
34. Dewachter I., et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 2002, 22(9):3445-3453.
35. Hillen H., et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010, 30(31):10369-10379.
36. Zhang L., et al. Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res 2006, 173(2):246-254.
37. Ambree O., et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging 2009, 30(8):1192-1204.
38. Escribano L., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35(7):1593-1604.
39. Greco S.J., et al. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2010, 19(4):1155-1167.
40. Harris J.A., et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci 2010, 30(1):372-381.
41. Knowles J.K., et al. Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiol Aging 2013, 34(8):2052-2063.
42. Spilman P., et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Res 2014, 1551:25-44.
43. Donkin J.J., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 2010, 285(44):34144-34154.
44. Howlett D.R., et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 2004, 1017(1-2):130-136.
45. Jardanhazi-Kurutz D., et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 2010, 57(4):375-382.
46. Matsuo K., et al. Vaccine efficacy of transcutaneous immunization with amyloid beta using a dissolving microneedle array in a mouse model of Alzheimer's disease. J Neuroimmunol 2014, 266(1-2):1-11.
47. McClean P.L., et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31(17):6587-6594.
48. Mori T., et al. Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 2012, 287(9):6912-6927.
49. Scholtzova H., et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 2008, 86(12):2784-2791.
50. Yan J.J., et al. Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease. Biol Pharm Bull 2013, 36(1):140-143.
51. Frydman-Marom A., et al. Orally administrated cinnamon extract reduces beta-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One 2011, 6(1):e16564.
52. Wang D., et al. beta2 adrenergic receptor: protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J Biol Chem 2013, 288(15):10298-10307.
53. Filali M., et al. Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP: PS1, and Mapt (3xTg-AD). Behav Brain Res 2012, 234(2):334-342.
54. Guzman-Ramos K., et al. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learn Mem 2012, 19(10):453-460.
55. Onishi T., et al. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. J Neurochem 2011, 119(6):1330-1340.
56. Platt B., et al. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One 2011, 6(11):e27068.
57. Ryan D., et al. Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent. Cell Mol Life Sci 2013, 70(14):2603-2619.
58. Polydoro M., et al. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29(34):10741-10749.
59. Cheng D., et al. Novel behavioural characteristics of female APPSwe/PS1DeltaE9 double transgenic mice. Behav Brain Res 2014, 260:111-118.
60. Davis K.E., et al. Episodic-like memory for what-where-which occasion is selectively impaired in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis 2013, 33(3):681-698.
61. Heneka M.T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006, 26(5):1343-1354.
62. Huang S.M., et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006, 281(26):17941-17951.
63. Middei S., et al. Progressive cognitive decline in a transgenic mouse model of Alzheimer's disease overexpressing mutant hAPPswe. Genes Brain Behav 2006, 5(3):249-256.
64. Scullion G.A., et al. Chronic treatment with the alpha2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 2011, 60(2-3):223-234.
65. Good M.A., Hale G. The Swedish mutation of the amyloid precursor protein (APPswe) dissociates components of object-location memory in aged Tg2576 mice. Behav Neurosci 2007, 121(6):1180-1191.
66. Zufferey V., et al. Maladaptive exploratory behavior and neuropathology of the PS-1 P117L Alzheimer transgenic mice. Brain Res Bull 2013, 94:17-22.
67. Morley J.E., et al. The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des 2012, 18(8):1123-1130.
68. Adler B.L., et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 2014, 35(4):793-801.
69. Yamaguchi Y., et al. Effects of ZSET1446/ST101 on cognitive deficits and amyloid beta deposition in the senescence accelerated prone mouse brain. J Pharm Sci 2012, 119(2):160-166.
70. Capurro V., et al. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One 2013, 8(2):e56870.
71. Meunier J., et al. The gamma-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Abeta1-42 seeding and short-term memory deficits in the Abeta25-35 mouse model of Alzheimer's disease. Eur J Pharm 2013, 698(1-3):193-199.
72. D'Agostino G., et al. Palmitoylethanolamide protects against the amyloid-beta25-35-induced learning and memory impairment in mice: an experimental model of Alzheimer disease. Neuropsychopharmacology 2012, 37(7):1784-1792.
73. Gomes G.M., et al. The selective A-type K+ current blocker Tx3-1 isolated from the Phoneutria nigriventer venom enhances memory of naive and Abeta(25-35)-treated mice. Toxicon 2013, 76:23-27.
74. Isono T., et al. Amyloid-β25-35 induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Neurosci Res 2013, 77(3):180-185.
75. Lu P., et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharm 2009, 157(7):1270-1277.
76. Tsunekawa H., et al. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 2008, 190(2):224-232.
77. Sipos E., et al. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease. Neuroscience 2007, 147(1):28-36.
78. He P., et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. Horm Behav 2013, 64(1):1-7.
79. Scali C., et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharm 1997, 325(2-3):173-180.
80. Luques L., Shoham S., Weinstock M. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. Exp Neurol 2007, 206(2):209-219.
81. McGrath J., et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13.
82. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10(1):40-68. (Image 5).
83. O'Grada C., Dinan T. Executive function in schizophrenia: what impact do antipsychotics have?. Hum Psychopharmacol 2007, 22(6):397-406.
84. Harvey P.D., McClure M.M. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 2006, 66(11):1465-1473.
85. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handb Exp Pharmacol 2012, (213):11-37.
86. Christensen T.O. The influence of neurocognitive dysfunctions on work capacity in schizophrenia patients: a systematic review of the literature. Int J Psychiatry Clin Pract 2007, 11(2):89-101.
87. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153(3):321-330.
88. Green M.F., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004, 56(5):301-307.
89. Moore H. The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy. Schizophr Bull 2010, 36(6):1066-1072.
90. Neill J.C., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010, 128(3):419-432.
91. Fallis R.J., et al. Adoptive transfer of murine chronic-relapsing autoimmune encephalomyelitis. Analysis of basic protein-reactive cells in lymphoid organs and nervous system of donor and recipient animals. J Neuroimmunol 1987, 14(2):205-219.
92. McIntosh A.L., et al. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology (Berl) 2013, 228(1):31-42.
93. Marco E.M., et al. Maternal deprivation effects on brain plasticity and recognition memory in adolescent male and female rats. Neuropharmacology 2013, 68:223-231.
94. Ozawa K., et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006, 59(6):546-554.
95. Giovanoli S., et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 2013, 339(6123):1095-1099.
96. Giovanoli S., Weber L., Meyer U. Single and combined effects of prenatal immune activation and peripubertal stress on parvalbumin and reelin expression in the hippocampal formation. Brain Behav Immun 2014, 40:48-54.
97. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014, 75(4):307-315.
98. Papaleo F., Lipska B.K., Weinberger D.R. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 2012, 62(3):1204-1220.
99. O'Tuathaigh C.M., et al. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci 2010, 31(2):349-358.
100. Arita I., et al. Evidence for spontaneous conversion of Mex- to Mex+ in human lymphoblastoid cells. Carcinogenesis 1990, 11(10):1733-1738.
101. Kendall I., et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 2011, 213(2-3):413-430.
102. McLean S.L., et al. Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 2011, 21(4):333-343.
103. Benito-Leon J., et al. Population-based case-control study of cognitive function in early Parkinson's disease (NEDICES). J Neurol Sci 2011, 310(1-2):176-182.
104. Dalaker T.O., et al. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord 2011, 26(2):297-301.
105. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968, 5(1):107-110.
106. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3(12):1301-1306.
107. Fernandes V.S., et al. Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease. Behav Brain Res 2012, 231(1):154-163.
108. Shin J.H., et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144(5):689-702.
109. Santos J.R., et al. Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine. Behav Brain Res 2013, 253:68-77.
110. Fernandes V.S., et al. Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson disease. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(6):1479-1483.
111. Sawamoto N., et al. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131(Pt 5):1294-1302.
112. Tessitore A., et al. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. J Neurosci 2002, 22(20):9099-9103.
113. Chao O.Y., Pum M.E., Huston J.P. The interaction between the dopaminergic forebrain projections and the medial prefrontal cortex is critical for memory of objects: implications for Parkinson's disease. Exp Neurol 2013, 247:373-382.
114. Goes A.T., et al. Neuroprotective effects of swimming training in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. Neuroscience 2014, 256:61-71.
115. Javitch J.A., et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985, 82(7):2173-2177.
116. Yabuki Y., et al. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience 2014, 259:126-141.
117. Ho S.C., et al. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model. Behav Brain Res 2014, 268:177-184.
118. Ho Y.J., et al. Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behav Brain Res 2011, 219(2):280-290.
119. McCormack A.L., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10(2):119-127.
120. Lyall K., Schmidt R.J., Hertz-Picciotto I. Maternal lifestyle and environmental risk factors for autism spectrum disorders. Int J Epidemiol 2014, 43(2):443-464.
121. Dos Santos A.C., et al. REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease. J Neurosci Res 2013, 91(11):1508-1516.
122. Li X., et al. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease. PLoS One 2013, 8(8):e71341.
123. Magen I., et al. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 2012, 35(6):870-882.
124. Moy S.S., et al. Mouse models of autism spectrum disorders: the challenge for behavioral genetics. Am J Med Genet C-Semin Med Genet 2006, 142C(1):40-51.
125. Kuusikko-Gauffin S., et al. Face memory and object recognition in children with high-functioning autism or Asperger syndrome and in their parents. Res Autism Spectr Disord 2011, 5(1):622-628.
126. Wolf J.M., et al. Specific impairment of face-processing abilities in children with Autism spectrum disorder using the let's face it! skills battery. Autism Res 2008, 1(6):329-340.
127. Bhattacharya A., et al. Genetic removal of p70 S6 kinase 1 corrects molecular: synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76(2):325-337.
128. Silverman J.L., et al. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 2013, 64:268-282.
129. Yang M., et al. Reduced excitatory neurotransmission and mild Autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 2012, 32(19):6525-6541.
130. Kane M.J., et al. Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to Autism. PLoS One 2012, 7(11).
131. Mychasiuk R., et al. Effects of rat prenatal exposure to valproic acid on behaviour and neuro-anatomy. Dev Neurosci 2012, 34(2-3):268-276.
132. Presti-Torres J., et al. Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: implications for an animal model of neurodevelopmental disorders. Neuropharmacology 2007, 52(3):724-732.
133. Fleminger S., Ponsford J. Long term outcome after traumatic brain injury. BMJ 2005, 331(7530):1419-1420.
134. Morris S., et al. Determinants of hospital costs associated with traumatic brain injury in England and Wales. Anaesthesia 2008, 63(5):499-508.
135. Gold E.M., et al. Functional assessment of long-term deficits in rodent models of traumatic brain injury. Regen Med 2013, 8(4):483-516.
136. Ferreira A.P., et al. The effect of NADPH-oxidase inhibitor apocynin on cognitive impairment induced by moderate lateral fluid percussion injury: role of inflammatory and oxidative brain damage. Neurochem Int 2013, 63(6):583-593.
137. Ferreira A.P., et al. HOE-140: an antagonist of B2 receptor, protects against memory deficits and brain damage induced by moderate lateral fluid percussion injury in mice. Psychopharmacology (Berl) 2014, 231(9):1935-1948.
138. Prins M.L., et al. Repeated mild traumatic brain injury: mechanisms of cerebral vulnerability. J Neurotrauma 2013, 30(1):30-38.
139. Zhao Z., et al. Neuroprotective effects of geranylgeranylacetone in experimental traumatic brain injury. J Cereb Blood Flow Metab 2013, 33(12):1897-1908.
140. Murray D.K.et al. The effects of exercise on cognition in Parkinson's disease: a systematic review. Transl Neurodegener 2014, 3(1):5.
141. Piao C.S., et al. Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury. Neurobiol Dis 2013, 54:252-263.
142. Dickendesher T.L., et al. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci 2012, 15(5):703-712.
143. Tong J., et al. Inhibition of Nogo-66 receptor 1 enhances recovery of cognitive function after traumatic brain injury in mice. J Neurotrauma 2013, 30(4):247-258.
144. Rachmany L.et al. Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-alpha. PLoS One 2013, 8(11):e79837.
145. Dachir S., et al. Inosine improves functional recovery after experimental traumatic brain injury. Brain Res 2014, 1555:78-88.
146. Tweedie D., et al. Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiol Dis 2013, 54:1-11.
147. Hamm R.J., et al. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994, 11(2):187-196.
148. Adelson P.D., et al. Motor and cognitive functional deficits following diffuse traumatic brain injury in the immature rat. J Neurotrauma 1997, 14(2):99-108.
149. O'Farrell E., MacKenzie J., Collins B. Clearing the air: a review of our current understanding of chemo fog. Curr Oncol Rep 2013, 15(3):260-269.
150. Wefel J.S., Schagen S.B. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012, 12(3):267-275.
151. Laquintana V., et al. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 2009, 6(10):1017-1032.
152. Janelsins M.C., et al. Prevalence: mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014, 26(1):102-113.
153. Kesler S.R., et al. Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav 2013, 7(4):501-510.
154. Deprez S., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32(3):480-493.
155. Silverman D.H., et al. Altered frontocortical: cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007, 103(3):303-311.
156. Vardy J., Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007, 63(3):183-202.
157. Bisen-Hersh E.B., Hineline P.N., Walker E.A. Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivors. Clin Cancer Res 2013, 19(11):3008-3018.
158. Oeffinger K.C., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355(15):1572-1582.
159. Fardell J.E., et al. The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Psychopharmacology (Berl) 2014, 231(5):841-852.
160. Fardell J.E., et al. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 2012, 220(1):183-193.
161. Pyter L.M., et al. Mammary tumors induce select cognitive impairments. Brain Behav Immun 2010, 24(6):903-907.
162. Mondie C.M., et al. The chemotherapy agent: thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res 2010, 209(1):66-72.
163. Gandal M.J., et al. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008, 157(1):95-104.
164. ElBeltagy M., et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res 2010, 208(1):112-117.
165. Seigers R., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186(2):168-175.